Charles River Laboratories International (NYSE:CRL) Issues FY25 Earnings Guidance

Charles River Laboratories International (NYSE:CRL) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided EPS guidance of $9.10-$9.60 for the period, compared to the consensus EPS estimate of $9.60. The company issued revenue guidance of $3.77-$3.87 billion, compared to the consensus revenue estimate of $3.87 billion. Charles River Laboratories International also updated its FY 2025 guidance to 9.100-9.600 EPS.

Analyst Ratings Changes

A number of research firms recently weighed in on CRL. Bank of America dropped their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. The Goldman Sachs Group reduced their price target on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. Finally, CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a research report on Monday, November 18th. Three equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $197.64.

Charles River Laboratories International Trading Up 6.9 %

CRL stock traded up $10.61 during midday trading on Wednesday, reaching $165.00. The company’s stock had a trading volume of 1,983,081 shares, compared to its average volume of 1,032,287. The business’s 50-day simple moving average is $174.59 and its 200-day simple moving average is $189.16. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International has a 52 week low of $150.79 and a 52 week high of $275.00. The stock has a market cap of $8.44 billion, a PE ratio of 20.65, a price-to-earnings-growth ratio of 5.91 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same quarter in the prior year, the business posted $2.46 EPS. The firm’s quarterly revenue was down 1.1% on a year-over-year basis. As a group, sell-side analysts expect that Charles River Laboratories International will post 10.16 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).